Certuity LLC Has $1.05 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Certuity LLC boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 20.2% during the 4th quarter, Holdings Channel reports. The institutional investor owned 2,580 shares of the pharmaceutical company’s stock after buying an additional 433 shares during the period. Certuity LLC’s holdings in Vertex Pharmaceuticals were worth $1,050,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. OFI Invest Asset Management purchased a new position in shares of Vertex Pharmaceuticals during the 3rd quarter valued at $25,000. Arlington Trust Co LLC increased its position in Vertex Pharmaceuticals by 97.1% in the 4th quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 33 shares during the last quarter. Fortitude Family Office LLC bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at $30,000. Baystate Wealth Management LLC boosted its holdings in Vertex Pharmaceuticals by 49.0% during the fourth quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after purchasing an additional 25 shares in the last quarter. Finally, NBC Securities Inc. bought a new stake in Vertex Pharmaceuticals in the 3rd quarter valued at $34,000. 90.96% of the stock is owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Price Performance

NASDAQ:VRTX traded down $2.16 during mid-day trading on Tuesday, hitting $394.04. 588,485 shares of the stock traded hands, compared to its average volume of 1,212,384. Vertex Pharmaceuticals Incorporated has a 12-month low of $320.01 and a 12-month high of $448.40. The company has a quick ratio of 3.78, a current ratio of 3.99 and a debt-to-equity ratio of 0.02. The company has a market cap of $101.84 billion, a PE ratio of 28.52, a price-to-earnings-growth ratio of 1.87 and a beta of 0.35. The business’s 50-day moving average price is $411.08 and its 200 day moving average price is $399.37.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share for the quarter, topping the consensus estimate of $3.85 by $0.35. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The firm had revenue of $2.52 billion for the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter in the prior year, the firm posted $3.33 earnings per share. On average, analysts expect that Vertex Pharmaceuticals Incorporated will post 14.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

VRTX has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. raised their price target on Vertex Pharmaceuticals from $390.00 to $438.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Truist Financial boosted their price target on shares of Vertex Pharmaceuticals from $456.00 to $508.00 and gave the stock a “buy” rating in a research report on Wednesday, January 31st. Canaccord Genuity Group reissued a “sell” rating and set a $371.00 price objective on shares of Vertex Pharmaceuticals in a research report on Friday, April 12th. StockNews.com lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 20th. Finally, UBS Group reduced their target price on Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating for the company in a report on Wednesday, April 17th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $429.45.

Insiders Place Their Bets

In other news, Chairman Jeffrey M. Leiden sold 2,656 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $419.51, for a total transaction of $1,114,218.56. Following the completion of the sale, the chairman now owns 27,644 shares in the company, valued at approximately $11,596,934.44. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, Chairman Jeffrey M. Leiden sold 2,656 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $419.51, for a total value of $1,114,218.56. Following the transaction, the chairman now owns 27,644 shares of the company’s stock, valued at $11,596,934.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Amit Sachdev sold 3,222 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $1,354,013.28. Following the sale, the executive vice president now directly owns 74,364 shares of the company’s stock, valued at approximately $31,250,727.36. The disclosure for this sale can be found here. Insiders have sold 12,381 shares of company stock worth $5,203,249 in the last ninety days. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.